Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Other Operating Expenses: 2022-2025

Historic Other Operating Expenses for Addex Therapeutics (ADXN) over the last 3 years, with Mar 2025 value amounting to $1.5 million.

  • Addex Therapeutics' Other Operating Expenses rose 1870.40% to $1.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.5 million, marking a year-over-year increase of 2617.37%. This contributed to the annual value of $207,275 for FY2024, which is 1684.05% up from last year.
  • As of Q1 2025, Addex Therapeutics' Other Operating Expenses stood at $1.5 million, which was up 1,250.35% from -$130,977 recorded in Q4 2024.
  • Over the past 5 years, Addex Therapeutics' Other Operating Expenses peaked at $1.5 million during Q1 2025, and registered a low of -$39.0 million during Q4 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $76,466 (2024), whereas its average is $177,731.
  • As far as peak fluctuations go, Addex Therapeutics' Other Operating Expenses crashed by 91.29% in 2023, and later skyrocketed by 1,870.40% in 2025.
  • Over the past 4 years, Addex Therapeutics' Other Operating Expenses (Quarterly) stood at -$39.0 million in 2022, then spiked by 99.31% to -$269,119 in 2023, then soared by 51.33% to -$130,977 in 2024, then skyrocketed by 1,870.40% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q1 2025, -$130,977 for Q4 2024, and $83,105 during Q3 2024.